Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments.
Dermata Therapeutics stock last closed at $1.47, up 2.8% from the previous day, and has decreased 73.91% in one year. It has underperformed other stocks in the Biotechnology industry by 0.72 percentage points. Dermata Therapeutics stock is currently +54.57% from its 52-week low of $0.95, and -76.39% from its 52-week high of $6.23.
As of Aug 19, 2026, there are 4.02M shares of DRMA outstanding. The market capitalization of DRMA is $5.91M. In the past 24 hours, 142,000 DRMA shares were traded.
You will need a brokerage account to access the NASDAQ market and buy DRMA stock.
Based on our analysis, eToro is the best online stock brokerage. eToro gives you:
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked the best brokerage, you'll need to fill out some personal details so you are able to invest in DRMA stock today.
Now that you've finished signing up on the best investment app, your next step is to transfer the money for your investment:
Watch this video walkthrough if you need help depositing funds into your new investment account.
After you have selected the best place to buy Dermata Therapeutics stock, it's very important to evaluate their stock prior to investing, so you can comprehend the risk as well as the upside.
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis.
You can view all of the due diligence checks on DRMA's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge DRMA's fair value.
Using relative valuations ratios:
You can access additional valuation analysis on DRMA's stock here.
You can dig deeper into what analysts are saying on the Dermata Therapeutics stock forecast page.
Over the past year, executives and large shareholders at DRMA have bought more shares than they have sold.
Kathleen D. Scott, Director of DRMA, was the latest DRMA insider to sell. They sold $13.09 worth of DRMA stock on Jun 16, 2026.
Dig into more about who owns DRMA stock here.
No, Dermata Therapeutics doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
There are two main options:
Hit the Open Trade button and eToro will place your order.
If you want more help buying stocks on eToro, click the how to video below:
Now that you own some DRMA shares, you'll want to stay up-to-date on your shares.
Start a watchlist to get notified of the latest news about your DRMA stock.
To reiterate, here are the 6 steps to buy Dermata Therapeutics stock:
If you need a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Dermata Therapeutics, hit the button below to create your watchlist.